Bio-XL
BioXL is an innovative biopharmaceutical company dedicated to transforming healthcare by developing therapies for undertreated medical conditions. The company focuses on scientific excellence and collaboration to create effective treatments that improve patient outcomes and quality of life. With a mission to empower lives and revolutionize treatment landscapes, BioXL targets pressing medical needs through advanced therapeutic solutions.
Industries
Nr. of Employees
small (1-50)
Products
Oncology therapeutic candidate for TNBC and PDAC
A therapeutic candidate with a described unique mechanism of action and a safety profile intended to treat multiple cancer types; positioned for use as an alternative to or in combination with chemotherapy.
AI-assisted breast cancer risk prediction test
Diagnostic test that augments current screening programs by combining digital pathology with big-data analytics and AI to improve prediction of breast cancer development risk.
Combination therapy candidate for slowing progression from MCI to dementia
A combination drug program targeting individuals with mild cognitive impairment to delay onset of dementia and preserve quality of life over extended periods.
Antimicrobial peptide therapeutics for resistant bacteria
Programs developing antimicrobial peptides intended to treat antibiotic-resistant infections while reducing negative impacts on the patient's microbiome.
Mitochondrial replacement therapy delivery vehicle
A delivery vehicle under development to enable safe administration in mitochondrial replacement therapy and related mitochondrial-targeted interventions; described as part of longevity/mitochondrial therapy research.
CeaseCancer
A novel disease-modifying biologic therapy for pancreatic cancer based on an optimized version of the human Klotho protein, engineered to enhance bioavailability and selectively target cancer cells.
Oncology therapeutic candidate for TNBC and PDAC
A therapeutic candidate with a described unique mechanism of action and a safety profile intended to treat multiple cancer types; positioned for use as an alternative to or in combination with chemotherapy.
AI-assisted breast cancer risk prediction test
Diagnostic test that augments current screening programs by combining digital pathology with big-data analytics and AI to improve prediction of breast cancer development risk.
Combination therapy candidate for slowing progression from MCI to dementia
A combination drug program targeting individuals with mild cognitive impairment to delay onset of dementia and preserve quality of life over extended periods.
Antimicrobial peptide therapeutics for resistant bacteria
Programs developing antimicrobial peptides intended to treat antibiotic-resistant infections while reducing negative impacts on the patient's microbiome.
Mitochondrial replacement therapy delivery vehicle
A delivery vehicle under development to enable safe administration in mitochondrial replacement therapy and related mitochondrial-targeted interventions; described as part of longevity/mitochondrial therapy research.
CeaseCancer
A novel disease-modifying biologic therapy for pancreatic cancer based on an optimized version of the human Klotho protein, engineered to enhance bioavailability and selectively target cancer cells.
Services
Engagement with investors for company-level investment or for investment in individual projects spun out as separate entities; presentation materials and partnering outreach.
Commercial development and market engagement for a pipeline of translational biopharma projects, including presenting projects at industry events and seeking collaborations.
Engagement with investors for company-level investment or for investment in individual projects spun out as separate entities; presentation materials and partnering outreach.
Commercial development and market engagement for a pipeline of translational biopharma projects, including presenting projects at industry events and seeking collaborations.
Expertise Areas
- Oncology drug development
- Diagnostic development and digital pathology
- Neurodegenerative therapeutic development
- Antimicrobial peptide discovery
Key Technologies
- Digital pathology
- AI-driven diagnostics
- Big-data analytics
- Antimicrobial peptides
News & Updates
BioXL will be attending MDI Expo 2025, aiming to meet industry leaders, exchange ideas, and explore collaboration opportunities in the medical diagnostics space.
BioXL will attend Biomed Israel 2025, the largest biotech conference in the country, in Tel Aviv from May 20–22, providing opportunities to connect with innovators, researchers, and companies shaping biotech's future.
BioXL has relocated to Sderot, marking a new chapter for the company and opening opportunities for growth.
In 2023, BioXL presented CancerPredict and CeaseCancer as breakthrough solutions in cancer diagnostics and therapy at the Biotechgate Partnering Event.
BioXL will be attending MDI Expo 2025, aiming to meet industry leaders, exchange ideas, and explore collaboration opportunities in the medical diagnostics space.
BioXL will attend Biomed Israel 2025, the largest biotech conference in the country, in Tel Aviv from May 20–22, providing opportunities to connect with innovators, researchers, and companies shaping biotech's future.
BioXL has relocated to Sderot, marking a new chapter for the company and opening opportunities for growth.
In 2023, BioXL presented CancerPredict and CeaseCancer as breakthrough solutions in cancer diagnostics and therapy at the Biotechgate Partnering Event.